ZW-33

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameZW-33

Drug Alias NameBi-Specific Azymetric Antibody Drug Conjugate (Zymeworks)bi-specific antibody drug conjugate (Zymeworks)ZW-33

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesZymeworks Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesZymeworks Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A